ES2176342T3 - Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico. - Google Patents

Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.

Info

Publication number
ES2176342T3
ES2176342T3 ES95936537T ES95936537T ES2176342T3 ES 2176342 T3 ES2176342 T3 ES 2176342T3 ES 95936537 T ES95936537 T ES 95936537T ES 95936537 T ES95936537 T ES 95936537T ES 2176342 T3 ES2176342 T3 ES 2176342T3
Authority
ES
Spain
Prior art keywords
type
sequences
hcv
new
subtipos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936537T
Other languages
English (en)
Other versions
ES2176342T5 (es
Inventor
Geert Maertens
Lieven Stuyver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176342(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of ES2176342T3 publication Critical patent/ES2176342T3/es
Application granted granted Critical
Publication of ES2176342T5 publication Critical patent/ES2176342T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DE NUCLEOTIDOS GENOMICOS Y A LAS SECUENCIAS DE AMINOACIDOS CORRESPONDIENTES A LA REGION DE CODIFICACION DE ESTOS GENOMAS. LA INVENCION SE REFIERE A NUEVAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV QUE SON DIFERENTES DE LAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV CONOCIDAS. EN PARTICULAR, LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DEL HCV TIPO 7, NUEVAS SECUENCIAS DEL HCV TIPO 9, NUEVAS SECUENCIAS DEL HCV TIPO 10 Y NUEVAS SECUENCIAS DEL HCV TIPO 11. LA PRESENTE INVENCION TAMBIEN SE REFIERE A NUEVAS SECUENCIAS DE LOS SUBTIPOS 1D, 1E, 1F Y 1G DEL HCV TIPO 1; NUEVAS SECUENCIAS DE LOS SUBTIPOS 2E, 2F, 2G, 2H, 2I, 2K Y 2L DEL HCV TIPO 2; NUEVAS SECUENCIAS DEL SUBTIPO 3G DEL HCV TIPO 3; NUEVAS SECUENCIAS DE LOS SUBTIPOS 4K, 4L Y 4M DEL HCV TIPO 4; A UN PROCESO PARA LA PREPARACION DE LAS MISMAS Y A SU USO PARA DIAGNOSTICOS, PROFILAXIS Y TERAPIAS. EN PARTICULAR, EN LA PRESENTE INVENCION SE PRESENTAN NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOSDE LAS REGIONES DEL NUCLEO, LAS REGIONES E1 Y LA NS5 DE NUEVOS HCV TIPO 7, 9, 10 Y 11, ASI COMO NUEVAS VARIANTES (SUBTIPOS) DE LOS HCV TIPO 1, 2, 3 Y 4. ESTAS SECUENCIAS NUEVAS DE HCV SON UTILES PARA DIAGNOSTICAR LA PRESENCIA GENOTIPOS O SEROTIPOS DEL HCV TIPO 1 Y/O TIPO 2 Y/O TIPO 3 Y/O TIPO 4 Y/O TIPO 7 Y/O TIPO 9 Y/O TIPO 10 Y/O TIPO 11 EN UNA MUESTRA BIOLOGICA. ADEMAS, LA DISPONIBILIDAD DE ESTAS NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOS PUEDE AUMENTAR LA SENSIBILIDAD GENERAL DE DETECCION DEL HCV Y DEBERIA DEMOSTRAR TAMBIEN SU UTILIDAD PARA FINES PROFILACTICOS Y TERAPEUTICOS.
ES95936537T 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. Expired - Lifetime ES2176342T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP94870166 1994-10-21
EP95870076 1995-06-28
EP95870076 1995-06-28

Publications (2)

Publication Number Publication Date
ES2176342T3 true ES2176342T3 (es) 2002-12-01
ES2176342T5 ES2176342T5 (es) 2010-02-09

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95936537T Expired - Lifetime ES2176342T5 (es) 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.

Country Status (12)

Country Link
US (2) US7129337B1 (es)
EP (2) EP1076092A3 (es)
JP (2) JPH10507643A (es)
AT (1) ATE218617T1 (es)
AU (1) AU702436B2 (es)
BR (1) BR9509421A (es)
CA (1) CA2201703A1 (es)
DE (1) DE69526973T3 (es)
DK (1) DK0804584T3 (es)
ES (1) ES2176342T5 (es)
PT (1) PT804584E (es)
WO (1) WO1996013590A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
CA2658218C (en) 1998-04-17 2014-10-28 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
CN1313864A (zh) * 1998-06-24 2001-09-19 基因创新有限公司 Hcv包膜蛋白颗粒∶用于疫苗接种的用途
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) * 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002013855A2 (en) * 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
EP1716250B1 (en) * 2004-01-07 2015-08-05 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
RU2267496C2 (ru) 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7465561B2 (en) 2005-06-30 2008-12-16 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using single probe analysis
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
MY153248A (en) 2006-07-14 2015-01-29 Ac Immune Sa Humanized antibody against amyloid beta
JP5674310B2 (ja) * 2006-08-25 2015-02-25 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖ ｅ２糖タンパク質
EP2463390A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
BRPI0812484A2 (pt) 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
TWI557136B (zh) 2007-06-12 2016-11-11 Ａｃ免疫公司 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
WO2009022939A1 (en) * 2007-08-09 2009-02-19 Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) Method for identifying the genotype and subtype of hepatitis c virus on a biological microchip
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
KR101851810B1 (ko) 2010-04-16 2018-04-26 에이씨 이뮨 에스.에이. 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
MX354662B (es) 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
EP2994754B1 (en) * 2013-05-10 2018-07-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Compositions and methods for simultaneous detection of hcv antigen/antibody
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3041864B1 (en) 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
KR102511343B1 (ko) 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
US20250179131A1 (en) 2022-03-04 2025-06-05 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
EP4547701A1 (en) 2022-07-01 2025-05-07 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225068B1 (en) † 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
CA2065287C (en) 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU642942B2 (en) 1989-12-18 1993-11-04 Wellcome Foundation Limited, The Viral agent
AU652941B2 (en) 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
ES2207633T3 (es) 1991-05-08 2004-06-01 Chiron Corporation Secuencias genomicas del vhc para diagnostico y tratamiento.
ATE229543T1 (de) * 1991-06-24 2002-12-15 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
EP0608261B1 (en) * 1991-09-13 2002-11-27 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
ES2065863T3 (es) 1991-11-21 2003-09-01 Common Services Agency Analisis para la deteccion de virus de la hepatitis c.
FI946066L (fi) * 1993-04-27 1994-12-23 Innogenetics Nv Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
PT804584E (pt) 2002-11-29
US6974864B2 (en) 2005-12-13
AU702436B2 (en) 1999-02-18
US20020183508A1 (en) 2002-12-05
DE69526973D1 (de) 2002-07-11
JP2005118044A (ja) 2005-05-12
BR9509421A (pt) 1997-09-30
AU3844095A (en) 1996-05-23
DE69526973T2 (de) 2003-01-02
ES2176342T5 (es) 2010-02-09
WO1996013590A2 (en) 1996-05-09
DE69526973T3 (de) 2010-01-07
EP0804584B1 (en) 2002-06-05
CA2201703A1 (en) 1996-05-09
EP0804584B2 (en) 2008-07-09
EP1076092A3 (en) 2001-03-28
WO1996013590A3 (en) 1996-08-15
DK0804584T3 (da) 2002-09-23
EP1076092A2 (en) 2001-02-14
JPH10507643A (ja) 1998-07-28
ATE218617T1 (de) 2002-06-15
EP0804584A1 (en) 1997-11-05
US7129337B1 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
ES2176342T3 (es) Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.
DE69330372T2 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
Kanto et al. Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation
Kolykhalov et al. Identification of a highly conserved sequence element at the 3'terminus of hepatitis C virus genome RNA
Xu et al. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon)
Widell et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications
BR9405334A (pt) Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
Mahony et al. Genetic analysis of bovine viral diarrhoea viruses from Australia
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
DE69126617T2 (de) Nanbv diagnostik: für die untersuchung auf hepatitis c verwendbare polynukleotide
WO1999029871A3 (fr) Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map)
Jiang et al. Phylogenetic analysis using E2 gene of classical swine fever virus reveals a new subgenotype in China
WO2001002601A3 (en) Cell-based assay systems for examining hcv ns3 protease activity
FI915443A0 (fi) Nanbv-diagnosfoerfarande:vid screening av hepatit-c virus anvaendbara polynukleotider.
CN108330210B (zh) 寨卡病毒、登革热病毒和基孔肯雅病毒核酸检测试剂盒及其用途
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
Lange et al. Virus isolate from carp: genetic characterization reveals a novel picornavirus with two aphthovirus 2A-like sequences
WO2000058524A3 (en) Typing of human enteroviruses
Widjojoatmodjo et al. Comparative sequence analysis of classical swine fever virus isolates from the epizootic in The Netherlands in 1997–1998
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
Fricke et al. A family of closely related bovine viral diarrhea virus recombinants identified in an animal suffering from mucosal disease: new insights into the development of a lethal disease in cattle
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
Giangaspero et al. Genetic variety of bovine viral diarrhea virus 2 strains isolated from sheep
AR021143A1 (es) Identificacion de genotipos senv
Borucki et al. The effect of mosquito passage on the La Crosse virus genotype